Surgical failure risk factors

Article

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma.

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma. These factors include preoperative IOP levels, patient age, number of preoperative medications and postoperative IOP spikes.

Masami Park, MD, PhD of the Sensho-kai Eye Institute, Kyoto, Japan and colleagues used multivariate regression analysis to determine the impact of various factors on postoperative IOP in cataract and primary open angle glaucoma (POAG) patients (n=180) with a mean preoperative IOP of 20.2±3.8 mmHg. Five years after surgery, the mean IOP for all patients was 15.3±2.6 mmHg. The surgery was defined as successful if patients achieved an IOP reduction of ≥20%, or an overall IOP of ≤17 mmHg. Without the use of postoperative medications, 31.4% of surgeries were successful; with or without medication, 47.2% were successful.

High preoperative IOP and lower age were found to be negatively correlated to surgical success in the "with or without medications" group; higher preoperative IOP, a greater number of preoperative medications and postoperative IOP spikes (to levels of >30 mmHg) were associated with surgical failure in the "without medications" group; gender and complications (including ruptured Descemet's membrane, hyphaema and fibrin formation) did not have an impact on the surgical success rate of either group.

The team concluded that the risk of failure to control IOP after phacoviscocanalostomy was increased by preoperative IOP levels, lower patient age, a high number of preoperative medications and postoperative IOP spikes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.